Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder

NCT01244490 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01244490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01244490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
January 17, 2011
Completion date
May 1, 2013
Enrollment
338 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder